Congenital dyserythropoietic anemia type IV in the genetic era: A rare neonatal case report of rapid identification with a review of the literature.

CDAN4 KLF1 congenital dyserythropoeitic anemia congenital hemolytic anemia genetic testing hydrops fetalis

Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
05 2023
Historique:
revised: 07 12 2022
received: 05 10 2022
accepted: 11 01 2023
pubmed: 18 2 2023
medline: 25 3 2023
entrez: 17 2 2023
Statut: ppublish

Résumé

Congenital dyserythropoietic anemia type IV (CDAIV) is a rare inherited hematological disorder, presenting with severe anemia due to altered erythropoiesis and hemolysis, with variable needs for recurrent transfusions. We present a case of a transfusion-dependent male newborn who presented at birth with severe hemolytic anemia, and required an intrauterine transfusion. Genetic testing rapidly identified a Kruppel-like factor 1 (KLF1) pathogenic variant (c.973G>A, p.E325K), known to be causative for CDAIV. This case highlights the advantages of next-generation sequencing testing for congenital hemolytic anemia: diagnostic speed, guidance on natural history, and optimized clinical management and anticipatory guidance for parents and clinicians. Additionally, we reviewed the literature for all CDAIV cases.

Identifiants

pubmed: 36798023
doi: 10.1002/pbc.30245
doi:

Types de publication

Review Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e30245

Informations de copyright

© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

Références

Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood. 2020;136(11):1274-1283.
Jamwal M, Aggarwal A, Sharma P, Bansal D, Das R. Congenital dyserythropoietic anemia type IV with high fetal hemoglobin caused by heterozygous KLF1 p.Glu325Lys: first report in an Indian infant. Ann Hematol. 2021;100(1):281-283.
Kohara H, Utsugisawa T, Sakamoto C, et al. KLF1 mutation E325K induces cell cycle arrest in erythroid cells differentiated from congenital dyserythropoietic anemia patient-specific induced pluripotent stem cells. Exp Hematol. 2019;73:25-37.e8.
Shefer Averbuch N, Steinberg-Shemer O, Dgany O, et al. Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. Eur J Haematol. 2018;101(3):297-304.
Russo R, Andolfo I, Manna F, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018;93(5):672-682.
Ravindranath Y, Johnson RM, Goyette G, Buck S, Gadgeel M, Gallagher PG. KLF1 E325K-associated congenital dyserythropoietic anemia type IV: insights into the variable clinical severity. J Pediatr Hematol Oncol. 2018;40(6):e405-e409.
Ortolano R, Forouhar M, Warwick A, Harper D. A case of congenital dyserythropoeitic anemia type IV caused by E325K mutation in erythroid transcription factor KLF1. J Pediatr Hematol Oncol. 2018;40(6):e389-e391.
de-la-Iglesia-Inigo S, Moreno-Carralero MI, Lemes-Castellano A, Molero-Labarta T, Mendez M, Moran-Jimenez MJ. A case of congenital dyserythropoietic anemia type IV. Clin Case Rep. 2017;5(3):248-252.
Jaffray JA, Mitchell WB, Gnanapragasam MN, et al. Erythroid transcription factor EKLF/KLF1 mutation causing congenital dyserythropoietic anemia type IV in a patient of Taiwanese origin: review of all reported cases and development of a clinical diagnostic paradigm. Blood Cells Mol Dis. 2013;51(2):71-75.
Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet. 2010;87(5):721-727.
Wickramasinghe SN, Illum N, Wimberley PD. Congenital dyserythropoietic anaemia with novel intra-erythroblastic and intra-erythrocytic inclusions. Br J Haematol. 1991;79(2):322-330.
Belgemen-Ozer T, Gorukmez O. A very rare congenital dyserythropoietic anemia variant-type IV in a patient with a novel mutation in the KLF1 gene: a case report and review of the literature. J Pediatr Hematol Oncol. 2020;42(6):e536-e540.
Ilsley MD, Huang S, Magor GW, Landsberg MJ, Gillinder KR, Perkins AC. Corrupted DNA-binding specificity and ectopic transcription underpin dominant neomorphic mutations in KLF/SP transcription factors. BMC Genomics. 2019;20(1):417.
Kulczynska K, Bieker JJ, Siatecka M. A Kruppel-like factor 1 (KLF1) mutation associated with severe congenital dyserythropoietic anemia alters its DNA-binding specificity. Mol Cell Biol. 2020;40(5):e00444-19.
Kulczynska-Figurny K, Bieker JJ, Siatecka M. Severe anemia caused by dominant mutations in Krüppel-like factor 1 (KLF1). Mutat Res Rev Mutat Res. 2020;786:108336.
Bajpayee A, Dubey A, Sonker A, Chaudhary RK. A case of severe foetal anaemia due to anti-M isoimmunisation salvaged by intrauterine transfusions. Blood Transfus. 2014;12(Suppl 1):s302-s304.
DiGuardo MA, Kester SJ, Mahaffey VJ, et al. Does transfusion of red blood cells impact germline genetic test results? J Pers Med. 2020;10(4):268.
Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. Blood. 2015;125(15):2405-2417.
Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux S. Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed. Elsevier; 2015.

Auteurs

Marc-Olivier Deguise (MO)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Sarah Blain (S)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Ewurabena Simpson (E)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Mira Liebman (M)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Emanuela Ferretti (E)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Division of Neonatology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH